Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should you Buy Dendreon Corporation (DNDN) on Earnings? – Johnson & Johnson (JNJ)

Page 1 of 2

Dendreon Corporation (NASDAQ:DNDN). investors have been on a perpetual roller coaster ride due to shifting expectations from Provenge. The company reported its quarterly results the other day and beat Street estimates. However, Provenge faces severe competition from Astellas’ (NASDAQOTH: ALPMY) Xtandi and Johnson & Johnson’s Zytinga. I believe that despite the recent positives it’s still too soon to be bullish on Dendreon Corporation (NASDAQ:DNDN), and I advise investors to wait for more good news before taking a long position.

Dendreon Corporation (NASDAQ:DNDN)Dendreon

Dendreon Corporation (NASDAQ:DNDN) is a biopharmaceutical company involved in the discovery and commercialization of novel therapeutics for oncology. Dendreon’s primary candidate is Provenge, an autologous cellular immunotherapy for cure of asymptomatic/minimally symptomatic, metastatic and castrate-resistant prostate cancer. Other products under development include DN24-02, carbonic anhydrase 9, carcinoembryonic antigen and TRPM8.

The company’s stock price has fluctuated between $3.69 and $13.89 during the last 52 weeks. This extreme fluctuation has been due to changing customer expectations from its star drug Provenge. Provenge was initially being hailed as a multibillion product, but underwhelming sales have been a problem. The company faces an increasingly competitive market, especially with the recent approval of Zytinga and Xtandi.

Dendreon Corporation (NASDAQ:DNDN) previously announced preliminary results for its fourth quarter. The Street was expecting Dendreon Corporation (NASDAQ:DNDN) to report an EPS of $-0.56 and it had already pre-announced quarterly revenues of $85.5 million. If we exclude the $3.8 million favorable adjustment to the company’s chargebacks reserve, revenues come down to $81.7, missing expectations by approx. 2%. As the table shows, the company has missed expectations in the last 3 quarters.

Earnings History 11-Dec 12-Mar 12-Jun 12-Sep
EPS Est -0.23 -0.63 -0.6 -0.86
EPS Actual 0.26 -0.7 -0.65 -1.04
Difference 0.49 -0.07 -0.05 -0.18
Surprise % 213.00% -11.10% -8.30% -20.90%

Source: Yahoo! Finance

Stock Mover

Dendreon’s stock is in a poor state, and recently went below its 200 day moving average of $5.74. This decline is due to investor expectations from these earnings. The company had to satisfy the following two concerns with these earnings:

i) The market was closely monitoring the cash position and margins on Provenge. The company has recent sold its Jersey factory and is also focusing on improving Provenge sales by reducing salesforce turnover. If it is able to beat EPS estimates and show an improved cash position, the stock market will react positively to earnings.

ii) Until the company churns out new FDA approvals, its valuations are tied to the fate of Provenge. Therefore the sales expectations for the next quarter will be crucial to the stock’s movement. The company has shown some improvement in preliminary results, especially in community sales of Provenge.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!